Acer MedicalROCO:6857 -2.13%52 EBITDA Margin % is -41.53% as of Dec. 2025. GuruFocus rates ROCO:6857 with a GF Score™ of 52/100 and a GF Value™ of NT$261.37 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Acer Medical ranks worse than 87.07% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Acer Medical's EBITDA for the
six
months ended in Dec. 2025 was NT$-12.43 Mil. Acer Medical's Revenue for the
six
months ended in Dec. 2025 was NT$29.93 Mil. Therefore, Acer Medical's EBITDA margin for the quarter that ended in Dec. 2025 was -41.53%.
Acer Medical (ROCO:6857) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Acer Medical EBITDA Margin % Related Terms
Acer Medical EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Acer Medical's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6857 vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, Acer Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acer Medical EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Acer Medical's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Acer Medical's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acer Medical (ROCO:6857) has a EBITDA Margin % of -41.53% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Acer Medical and its competitors. According to the industry distribution chart, Acer Medical ranks #579 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 87.1%.
Is Acer Medical's EBITDA Margin % too high?
Acer Medical's current EBITDA Margin % is -41.53%. Based on the distribution chart, Acer Medical ranks #579 out of 665 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Acer Medical has a GF Score™ of 52/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Acer Medical's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Acer Medical ranks #579 out of 665 companies for EBITDA Margin %. This places Acer Medical in the lower half of its industry. The industry median EBITDA Margin % is 10.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Acer Medical and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acer Medical's current EBITDA Margin % is -41.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acer Medical stock overvalued right now?
Based on GuruFocus' analysis, Acer Medical (ROCO:6857) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$261.37, compared to a current price of NT$92.00 — trading 64.8% below its estimated fair value. The current EBITDA Margin % is -41.53%. Acer Medical's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Acer Medical (ROCO:6857), the current EBITDA Margin % is -41.53% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acer Medical (ROCO:6857) Overvalued in 2026?
Based on GuruFocus' analysis, Acer Medical stock appears to be undervalued.
The current stock price of NT$92.00 is trading 64.8% below its estimated GF Value™ of NT$261.37.
GuruFocus considers Acer Medical to be Significantly Undervalued.
Key valuation signals for ROCO:6857:
EBITDA Margin %: -41.53%
GF Value™: NT$261.37 vs. price of NT$92.00 (64.8% below fair value)
No single metric tells the full story. See the ROCO:6857 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acer Medical Inc focuses on improving human health and well-being through artificial intelligence. It focuses on applying artificial intelligence and large data to the area of healthcare. Acer Medical is capable of designing, developing, commercializing, as well as implementing AI solutions in medical institutions.
52GF Score
Get the complete analysis for ROCO:6857
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6857 has been successfully added to your 
